Drug Discovery

Cognitive Enhancement

Pharmacological Reversal of the Behavioral and Electrophysiological Sequelae of A-beta Deposition

Investigator(s): Michael Shelanski MD, PhD

Institution(s): Taub Institute, Columbia University, NY

Duration: 2004 - 2005

Summary:

Current therapies for Alzheimer’s disease (AD) have focused on agents thatimprove cholinergic function (e.g. Aricept, Exelon and Reminyl), decrease glutamate toxicity(memantine) and more recently agents that decrease ß-amyloid peptide (Aß). Theaccumulation of Aß in brain believed to be is toxic to nerve cells resulting in a loss of